Neuralstem, Inc. (CUR) Stock: A Biotech Stock That’s Seeing Strong Declines

0

Neuralstem, Inc. (CUR) is headed down in the market today. The stock, one that is focused on the biotech industry, is currently priced at $0.31 after falling -11.71% so far in today’s session. As it relates to biotech stocks, there are a number of aspects that have the potential to generate price movement in the market. One of the most common is news. Here are the most recent trending headlines centered around CUR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-03-19 02:55PM Germantown biopharma stock on the brink of delisting
May-16-19 07:07AM Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells
May-14-19 04:30PM Neuralstem Reports First Quarter 2019 Fiscal Results
May-06-19 07:00AM Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors
Apr-29-19 10:02AM Some Neuralstem (NASDAQ:CUR) Shareholders Have Copped A 99% Share Price Wipe Out

Nonetheless, when making an investing decision, prospective investors should look into far more than news, especially in the highly speculative biotechnology industry. Here’s what’s happing when it comes to Neuralstem, Inc..

Trends That We’ve Seen From CUR

Although a move down on a single session, like the fall that we’re seeing from Neuralstem, Inc. might make some investors upset, a single session move by itself should not be the basis of a decision to, or not to, invest in a company. It is generally important to look at trends experienced by the stock beyond a single session. In the case of CUR, here are the movements that we have seen:

  • Past 5 Trading Sessions – In the past 5 trading sessions, CUR has produced a change in price that amounts to -13.92%.
  • Monthly – The return on investment from Neuralstem, Inc. over the past 30 days comes to -31.89%.
  • Past Quarter – Over the last 3 months, the stock has produced a ROI of -38.65%
  • Past 6 Months – Over the last six months, we’ve seen a change that equates to -26.21% from the stock.
  • Year To Date – Since the the last trading session of last year CUR has generated a return on investment of -1.02%.
  • Annually – Lastly, throughout the past full year, we’ve seen movement that comes to -73.28% from CUR. In this period of time, the stock has traded at a high of -80.51% and a low of 23.85%.

Key Ratios

Looking at a few key ratios associated with a stock generally gives traders a look of how risky and/or potentially profitable a an investment option may be. Below are some of the important ratios to look at when looking at CUR.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it means that more investors are expecting that the price of the stock is going to go down. Across the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the sector. Nonetheless, with regard to Neuralstem, Inc., the stock’s short ratio amounts to 1.36.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Essentially, they measure whether or not a company can pay for its debts when they come due with only current assets or quick assets. In the biotech sector, several companies are heavily reliant on continued support from investors, the current and quick ratios can look bad. Nonetheless, quite a few better companies in the biotechnology space do have strong current and quick ratios. When it comes to CUR, the quick and current ratios work out to 3.80 and 3.80 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price of the stock. In this particular case, that ratio is 0.18.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is an important ratio to consider. In the case of CUR, the cash to share value is 0.

What Analysts Think About Neuralstem, Inc.

While it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts in order to validate your own before making investment decisions in the biotech industry. Here are the recent moves that we have seen from analysts as it relates to CUR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-07-16 Initiated Aegis Capital Buy
Aug-29-16 Initiated ROTH Capital Buy $1.20
Apr-28-15 Initiated MLV & Co Buy $6
Feb-18-15 Initiated Brean Capital Buy $8
Sep-08-14 Initiated H.C. Wainwright Neutral

What Are Big Money Players Doing With Neuralstem, Inc.

An interesting fact that I’ve come to understand so far in my short time alive, or somewhat alive is that good investors tend to follow big money. In general, investors that are trying to keep their investments relatively safe will pay close attention to trades made by institutions as well as insiders of the company. With that said, where is the big money in regard to CUR? Here’s the scoop:

Institutions own 5.20% of the company. Institutional interest has moved by -65.01% over the past three months. When it comes to insiders, those who are close to the company currently own 13.52% percent of CUR shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 20.80M shares of Neuralstem, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CUR has a float of 17.55M.

I also find it important to take a look at the short float. Think about it, if a high portion of the float available for trading is shorted, the overall feeling in the market is that the stock is headed for a steep decline. As far as CUR, the percentage of the float that is sold short is 1.37%. Most investors would say that a high short percent of the float is anything over 40%. Through my work, I have calculated that any short percent of the float over 26% is likely a a play that could prove to be very risky.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, CUR has generated revenue in the amount of $18.80% with earnings coming in at 38.10%. On a quarter over quarter basis, earnings have seen movement of -20.40% and revenue has seen movement of 0.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but, like humans, I learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at information? If so, write a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here